Introduction {#Sec1}
============

Infantile hypertrophic pyloric stenosis (IHPS) affects 1.9 of every 1000 live births \[[@CR1]\] making the condition the most common cause of surgical intervention in the first 6 months of life \[[@CR2]\]. IHPS is characterised by hypertrophy of the pylorus resulting in gastric outlet obstruction, leading to the infant presenting with projectile vomiting and severe dehydration.

Although genetics \[[@CR3]\] and male sex \[[@CR4]\] have been identified as risk factors, the aetiology of IHPS is largely unknown. Furthermore, changes in the incidence rates of IHPS have led to the hypothesis that environmental factors may have a role in the development of the condition \[[@CR5]\].

Several studies have identified a strong relationship between exposure to erythromycin and development of IHPS \[[@CR6]\]---with some studies identifying an eight to tenfold increase in risk of developing IHPS when erythromycin was administered in the first 2 weeks of life \[[@CR7]\]. One theory is that erythromycin interacts with the receptors of motilin, an intestinal peptide that stimulates contraction of gut smooth muscle. This interaction could therefore produce contraction of the gastric and pyloric bulb, resulting in hypertrophy of the pylorus \[[@CR8]\]. However, other studies refute the association between erythromycin treatment in infants and the development of IHPS entirely, identifying no association \[[@CR9]\].

The aim of this study was to perform a systematic review and meta-analysis of published studies to clarify and quantify the relationship between any post-natal exposure to erythromycin and the development of pyloric stenosis. A second aim was to determine whether treatment with erythromycin within the first 2 weeks of life increased the magnitude of this association.

Methods {#Sec2}
=======

A systematic literature search was performed of all studies published from 1 January 1970 and 1 July 2016, using PubMed, Ovid Medline, Embase and the Cochrane Library with the medical subject heading (MeSH) terms and text words: (infantile hypertrophic pyloric stenosis OR pyloric stenosis) AND (macrolide OR erythromycin) and similar variants. Search criteria were limited to studies published in the English language, and by age of subject (age less than 6 months) to ensure that only infantile cases of pyloric stenosis were included for analysis. Reference lists of included articles and abstract lists of relevant national and international meetings were also searched to identify other studies which could be included for analysis.

Studies were then assessed for inclusion by two authors independently (LM, SE). Our aim was to ensure that all robust studies which reported an association between erythromycin exposure and subsequent development of IHPS were included for analysis. Studies were excluded for several reasons; insufficient data available for analysis, unable to extract suitable data to allow meta-analysis, type of macrolide not explicitly stated, route of administration was only to the mother (either ante-natal or post-natal transfer in breast milk) or if route of administration of erythromycin was ambiguous. When more than one publication from an overlapping cohort was identified, the largest study with the most rigorous methodology was selected. Duplicate data, already available as a published paper, which had been published in the form of letters to the editor of journals was also excluded. The selection process is illustrated in Fig. [1](#Fig1){ref-type="fig"}. Data was independently extracted by the authors.Fig. 1Diagram of workflow in the systematic review and meta-analysis

The meta-analysis was performed using Mantel--Haenszel random effects model using the Cochrane Collaboration's Review Manager (RevMan 5.3, the Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen) to calculate the overall odds ratio (OR), 95 % confidence interval (CI) and *I* ^2^ test statistic for heterogeneity of studies.

Publication bias was assessed using the funnel plot method.

Results {#Sec3}
=======

Literature search identified 115 papers for potential inclusion; 104 did not meet the criteria for inclusion and were excluded from the meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). The remaining nine studies comprised two randomised control trials (one study on erythromycin used for improving enteral feeding tolerance and a second study on oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants), and seven retrospective cohort studies. The characteristics of eligible studies are shown in Table [1](#Tab1){ref-type="table"}.Table 1A summary of the studies included detailing country of origin, study type, data source, total number of infants studied, number of infants within study group who were exposed to erythromycin, and subsequently developed IHPS and the weight of the study in the meta-analysisStudy (year)CountryStudy typeSource of dataTotal number of infantsNumber of infants exposed to erythromycin who developed IHPSStudy weight (%)Ng et al. (2001) \[[@CR10]\]ChinaRandomised control trialPreterm infants admitted to the neonatal unit at Prince of Wales Hospital, Hong Kong from November 1998--May 2000290/Cooper et al. (2002) \[[@CR11]\]United StatesCohort studyMedicaid or TennCare (Tennessee's program for Medicaid enrollees and uninsured individuals) births in Tennessee from 1985--1997306891918Eberly et al. (2015) \[[@CR12]\]United StatesCohort studyInfants born between 1 June 2001 and 1 April 2012 registered with the TRICARE Management Activity military health system (MHS) database10699001719.2Mahon et al. (2001) \[[@CR13]\]United StatesCohort studyInfants born from 1 June 1993--31 December 1999, Wishard Hospital, Indianapolis14407415Honein et al. (1999) \[[@CR14]\]United StatesCohort studyInfants born in a community hospital from January--February 199912575.3Ludvigsson et al. (2016) \[[@CR9]\]SwedenCohort studyNationwide cohort of infants born between July 2005 and December 201058225605.5Ericson et al. (2015) \[[@CR15]\]United StatesCohort studyInfants from 348 NICUs managed by the Pediatrix Medical Group between 1997--2012190011017.9Lund et al. (2014) \[[@CR16]\]DenmarkCohort studyAll liveborn singleton infants in Denmark between 1 January 1996 and 31 December 20119993781619.1Mohammadizadeh et al. (2010) \[[@CR17]\]IranRandomised control trialUncomplicated preterm infants (28--34 weeks) born in Shahid-Beheshti and Al-Zahra Hospitals affiliated with the Isfahan University of Medical Sciences350/

Selected cohort studies were published between 1999 and 2016. Cases were defined as infants who developed pyloric stenosis in infancy (age less than 6 months), whilst controls were patients who did not develop pyloric stenosis during the study period. National birth registries, hospital and community health records were the main data sources for both groups. Diagnosis of pyloric stenosis was confirmed from clinical diagnosis recorded in health records. The total number of infants included was 3,008,453, of whom 16,431 had received erythromycin. Sixty-three infants developed IHPS after receiving erythromycin, whereas 4632 infants developed IHPS without having received erythromycin. In the two randomised studies, the total number of infants included was small, and there were no cases of pyloric stenosis in either the exposed or the unexposed groups, so that they could not contribute to the odds ratio. Overall, there was a significant association between erythromycin exposure and subsequent development of pyloric stenosis \[OR 2.45 (1.12--5.35), *p* = 0.02, Fig. [2](#Fig2){ref-type="fig"}\]. However, there was significant heterogeneity between the studies (*I* ^2^ = 84 %, *p* \< 0.0001). A funnel plot of published studies demonstrated possible asymmetry indicating potential publication bias, although asymmetry is difficult to determine with only seven studies contributing to the funnel plot (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Forest plot comparing the incidence of IHPS between infants with exposure to erythromycin at any time and infants who had never been exposed to erythromycin Fig. 3Funnel plot of included studies

A further analysis was performed to identify the relationship between exposure to erythromycin in the first 14 days of life and development of IHPS. Only four of the selected nine studies documented whether exposure had occurred within this period. In these studies, the association between erythromycin exposure and subsequent development of pyloric stenosis was even stronger \[OR 12.89 (7.67--2167), *p* \< 0.00001\] (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Forest plot comparing the incidence of IHPS between infants with exposure to erythromycin within the first 2 weeks of life and infants who have never been exposed to erythromycin

Discussion {#Sec4}
==========

This study is the only published meta-analysis which reviews the association between erythromycin use in infants and subsequent development of IHPS and provides a comprehensive estimate of this risk.

The key finding of the meta-analysis is that the OR of developing IHPS after any erythromycin in the post-natal period is two and a half (OR = 2.45) times greater than in those infants not exposed to the drug. Furthermore, subgroup analysis of included studies identified a 12-fold increase in the development of IHPS when erythromycin was administered in the first 14 days of life; a value significantly higher than previously reported.

Literature search did not identify any published meta-analyses and only one systematic review. Maheshwa et al. \[[@CR7]\] investigated the relationship between young infants treated with erythromycin and risk of developing hypertrophic pyloric stenosis by analysis of six papers published between 1976 and 2005. Their review concludes that while more evidence is required regarding the relationship between erythromycin use and IHPS, young infants exposed to erythromycin in the first few weeks of life are at a greater risk of IHPS. Their analysis is also in agreement with this study in stating that the risk appears to be highest in the first 2 weeks of life, but stipulates that this occurs in term or near-term infants or when antibiotics are administered for more than 14 days.

It should be noted that two papers included in our analysis, Ng et al. \[[@CR10]\] and Mohammadizadeh et al. \[[@CR17]\], study populations of preterm infants alone whilst Ericson et al. \[[@CR15]\] have analysed only infants within a neonatal intensive care (NICU) environment. Therefore, variability of the calculated OR may occur due to the inclusion of these groups of infants within the analysis. This could also explain the high I^2^ value representing heterogeneity.

In addition, significant geographical bias exists with five of the nine studies selected for analysis focusing on populations from the United States. Such bias may partly result from the literature search criteria which only include studies published in the English language.

A further source of bias occurs due to the greater proportion of cohort studies included for analysis in comparison to other study types. There were no published case--control studies which reviewed this relationship. However, this may result from the ethical feasibility of designing a study which may prevent an infant from receiving erythromycin to treat infection in cases where alternative antibiotics are contraindicated or insensitive.

Bias {#Sec5}
----

In accounting for the variability of the calculated OR and the significant heterogeneity present between the nine included studies, several factors must be considered. An important factor is that the incidence of IHPS is heterogeneous, varying significantly according to ethnicity, sex and time. There is also a significant genetic component to development of IHPS, so that any conclusive study should also include analysis of confounders, such as gender, ethnicity, and genetic status.

Risk/benefit {#Sec6}
------------

Erythromycin is commonly indicated within the neonatal population for prophylaxis following Chlamydia trachomatis infection \[[@CR18]\] in preventing conjunctivitis or pneumonia and in the treatment of pertussis \[[@CR14]\]. In addition, erythromycin has also been utilised in the treatment of gastrointestinal dysmotility within this population \[[@CR10]\].

Although this study concludes that OR for developing IHPS following erythromycin exposure is high, particularly in the first 14 days of life, physicians must evaluate the risk--benefit ratio in making an informed decision as to whether the potential morbidity or mortality of an infection such as pertussis is outweighed by the risk of developing IHPS. It should also be noted that the absolute risk of developing IHPS following erythromycin exposure is not high \[0.4 % (95 % CI 0.3--0.5 %) in those receiving erythromycin at any time, and 2.6 % (95 % CI 1.5--4.2 %) in those receiving erythromycin in the first 14 days\]. However, consideration should be made to the fact that despite the indications, macrolides (including erythromycin) remain unlicensed for use by the US Food and Drug Administration for use in infants less than 6 months.

Limitations {#Sec7}
-----------

The main limitation of this study is the lack of published studies investigating the relationship between erythromycin use and development of IHPS. Furthermore, differences existed between study designs which may have led to further variability in the calculated ORs. In particular, studies often categorised cases into time periods which often varied between studies resulting in their exclusion despite rigorous methodology. Studies which did not explicitly state that the macrolide administered was erythromycin were also excluded. In addition, all cohort studies included were performed retrospectively, thus having a negative effect on the quality of the data. Our study aimed to exclusively review the effect of neonatal administration of erythromycin on the risk of subsequently developing IHPS. However, the question remains as to whether other methods of exposure (such as maternal administration en-utero or postnatally from absorption via breast milk) may be associated with similar levels of risk. With regard to exposure via breastfeeding, Sorensen \[[@CR19]\] concludes that an increased risk of developing IHPS exists following maternal macrolide administration postnatally \[OR 2.7 (95 % CI 0.7--11.1)\]. However, this is contrasted by two papers by \[[@CR20]\] Goldstein et al. and \[[@CR21]\] Salman et al. which found no correlation between breast milk exposure and IHPS. The data on exposure via breast milk was too sparse to meta-analyse.

There is also some evidence in the literature that administration of erythromycin to pregnant women may result in the fetus developing IHPS as an infant. Kallen \[[@CR22]\] report a risk ratio of 2.51 (95 % CI 0.92--5.46) of infants developing IHPS in cases where their mother had received erythromycin after the first antenatal visit. However, studies by Lin \[[@CR23]\] and Louik \[24\] found no relationship between prenatal exposure to macrolide and pyloric stenosis.

Furthermore, from the papers analysed, there is no report regarding the family history, and therefore it remains unclear if a genetic predisposition is required to increase the risk of acquiring IHPS following administration of erythromycin. With such significant variability in the available literature in reporting the exact nature and magnitude of risk of erythromycin administration (during both fetal and neonatal development) further study is warranted.

Conclusion {#Sec8}
==========

This study provides clinicians with the first comprehensive estimate for the OR of infants developing IHPS when exposed to erythromycin. Physicians should utilise this study as a tool in evaluating the risk--benefit ratio of administering erythromycin for treatment and prophylaxis of infections in neonates versus the risk of developing IHPS. However, in determining whether erythromycin is a suitable treatment for infections within this group, the limitations of this study should be noted. In particular, publications bias and the lack of high-quality, with significant patient numbers should be considered.
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